Status:
COMPLETED
Evaluating Intercostobrachial Nerve Block's Effect on Pain Control After Shoulder Replacement
Lead Sponsor:
University of Texas Southwestern Medical Center
Conditions:
Postoperative Pain, Acute
Shoulder Pain
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Interscalene blocks are frequently performed to decrease postoperative pain after shoulder surgeries and are considered the gold standard for pain control after this type of surgery. Some patients rep...
Eligibility Criteria
Inclusion
- Adult patients 18-80 years old
- Adult patient's BMI \<= 35
- Individuals presenting for primary total shoulder arthroplasty or reverse total shoulder arthroplasty
- Anticipated discharge home same day of surgery
- Patient is able to provide informed consent to participate in the study.
Exclusion
- Patient presenting for revision shoulder surgery
- Allergy to amide local anesthetic, liposomal bupivacaine or other medication involving liposomal formulation
- Preexisting neurological deficits involving or potentially involving the ipsilateral brachial plexus
- Preexisting contralateral vocal fold paralysis or recurrent laryngeal paralysis
- Psychiatric or cognitive disorders that could interfere with perioperative evaluation including drug or alcohol abuse
- Chronic pain conditions
- Preoperative opioid use
- Moderate to severe pulmonary disease
- Moderate to severe sleep apnea
- Planned postoperative admission.
- Unplanned postoperative admission
- Any contraindication to interscalene or intercostobrachial nerve block including any local disorder of the skin where blockade is to be performed which would prevent safe performance of the block
- Any coagulation abnormality which would be a contraindication for block placement
- Preoperative chronic renal dysfunction requiring renal replacement therapy or CrCl \< 60
- Sulfa allergy (or other reason patient cannot receive celecoxib)
- Allergy or intolerance to any medication in the protocol
- Body mass index \>35
- Pregnancy
- Incarceration
- ASA classification greater than 3
- Inability to provide informed consent
- Refusal to participate in the study
Key Trial Info
Start Date :
September 10 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2025
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT06042608
Start Date
September 10 2024
End Date
June 30 2025
Last Update
October 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas Southwestern Medical Center
Dallas, Texas, United States, 75390